- Home
- HG vs XENE Comparison
HG vs XENE Comparison
Compare HG & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HG | XENE |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | Bermuda | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.2B |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HG | XENE |
|---|---|---|
| Price | $28.65 | $54.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $31.25 | ★ $67.17 |
| AVG Volume (30 Days) | 415.4K | ★ 1.7M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.84% | N/A |
| EPS Growth | ★ 51.23 | N/A |
| EPS | ★ 5.55 | N/A |
| Revenue | ★ $2,905,524,000.00 | $311,000.00 |
| Revenue This Year | $1.87 | N/A |
| Revenue Next Year | $12.41 | $2,436.26 |
| P/E Ratio | $5.27 | ★ N/A |
| Revenue Growth | ★ 24.70 | N/A |
| 52 Week Low | $16.80 | $26.74 |
| 52 Week High | $32.21 | $62.91 |
Technical Indicators
Market Signals| Indicator | HG | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 44.19 | 58.97 |
| Support Level | $28.06 | $39.93 |
| Resistance Level | $28.71 | $62.91 |
| Average True Range (ATR) | 0.65 | 2.05 |
| MACD | -0.06 | -0.33 |
| Stochastic Oscillator | 38.72 | 20.46 |
Price Performance
Historical ComparisonAbout HG Hamilton Insurance Group Ltd. Class B
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.